Ambrose announced it is acquiring AM-Pharma’s Phase Ib-ready hypophosphatasia program ilofotase alfa for $181 million, aiming to bring an enzyme replacement therapy to adults with no approved treatment option. The deal includes an upfront payment to AM-Pharma shareholders and up to $181 million in milestone payments tied to commercialization, with ilofotase alfa carrying orphan drug designation from the FDA and EMA.